VANCOUVER, BC, May 31, 2022 – Andira Pharmaceuticals is proud to announce the hiring of Eurofins Discovery to conduct pre-clinical research on Andira’s lead asset, a cannabinoid-based injectable antibiotic for treatment of hospital-acquired infection. Eurofins Discovery is the leading contract research organization (CRO) brand with over 35 years of success providing complete product solutions and services for drug discovery.
“We are pleased to be working with Eurofins Discovery’s scientists to examine efficacy of our formulation in well-characterized models of infection,” Andira CEO Dr. Dana Lambert said. “They are recognized globally as a top-tier CRO and a leader in the field of infectious disease; Eurofins is the right partner for us to advance our lead candidate forward in pre-clinical development.”
Eurofins Discovery specializes in providing drug research and development services globally utilizing its portfolio of over 5,300 biological tests ranging from molecular assays to cell-based models through proof-of-concept models.
The research will focus on treatment for the rising health threat of hospital-acquired infection, which represents an estimated global market of USD $10.6 billion. Drug-resistant “superbugs” like methicillin-resistant Staph aureus (MRSA) and vancomycin-resistant enterococcus (VRE) present serious challenges for infection control. VRE infection in hospitals carries a significant chance of mortality, while the development pipeline of novel antibiotics to combat the superbug problem remains limited.
“Our work with Eurofins will inform the next phase of development in a way we hope will lead to a clinically useful solution to antimicrobial resistance,” Dr. Lambert said. “Early research on our cannabinoid-based antibiotic is encouraging.”
Andira is a science-driven company with the ability to translate in-depth research information into effective solutions for patients. Building upon pre-existing data, Andira has significantly advanced the frontiers of knowledge on the pharmacotherapeutic properties of cannabinoids.
About Eurofins Discovery
Eurofins Discovery is recognized as the industry leader for providing drug discovery researchers with the largest and most diverse portfolio of standard and custom in vitro safety & pharmacology assays and panels for drug screening and profiling. In addition to in vitro safety pharmacology strengths, we also offer a broad portfolio of over 3,500 drug discovery services and 1,800 products. These include in vitro assays, cell-based phenotypic assays, safety pharmacology and efficacy, ADME toxicology, medicinal chemistry design, synthetic chemistry, and custom proteins and assay development capabilities. We support a variety of drug discovery targets such as GPCRs, Kinases, Ion Channels, Nuclear Hormone Receptors and other proteins & enzymes. The Eurofins Discovery capabilities, expertise, knowledge and skill sets enable the company to provide clients the benefit of being able to work with a single outsourcing provider (CRO) for all their drug discovery programs.